Prevalence of PER-1- type Extended-Spectrum Beta-Lactamaes in Clinical Strains of Pseudomonas aeruginosa Isolated from Tabriz, Iran

Document Type: Original Article


1 Department of Microbiology, Faculty of Medicine, and *Research Center of Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Clinical Laboratory Sciences, Faculty of Paramedicine, Urmia University of Medical Science


The aim of this study was to investigate the presence of PER-1-type ESBLs in drug resistant Pseudomonas aeruginosa isolates.
Materials and Methods
During one-year period (2008-2009), following isolation and identification of 56 P. aeruginosa, the E-test method was performed for determination of minimal inhibitory concentration of ceftazidim. The isolates that they had MIC≥16 µg/ml against ceftazidim were used for determination of ESBL-producing by combined disk test (CDT) and double disk synergy test (DDST) methods. Bla PER-1genewas investigated by PCR.P. aeruginosa KOAS was used as positive control.
Twenty-nine (51.78%) out of fifty six isolates had MIC≥16 µg/ml to ceftazidime, twenty two (75.86%) of them were ESBL producers. Some isolates (27.5%) contained bla PER-1 gene.
PER-1-type ESBLs producing P.aeruginosa has not been reported previously in Tabriz but there has been a rather high prevalence of it.


1. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump (s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994; 38:1742-1752.
2. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad – spectrum β- lactamases conferring transferable resistance to newer β- lactam  agents in Enterobacteriaceae hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
3. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47:2385-2392.
4. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother 1994; 38: 104-114.
5. Vahaboglu H, Oztürk R, Aygün G, Coşkunkan F, Yaman A, Kaygusuz A, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-2269.
6. MacFaddin JF.Biochemical tests for identification of medical bacteria. 3rded. New York : Liooincott Williams AND Wilkins; 2000.p.689-690,705-771.
7. Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing: Document M10 – S15.CLSI. Wayne, PA, USA, 2005.
 8. Naas T, Nordmann P, Heidt A. Intercountry transfer of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii from Romania. Int J Antimicrob Agents 2007; 29: 226–228.                                     
9. Akhi MT, Farzaneh F, Oskouei M. Study of enterococcal susceptibility patterns isolated from clinical specimens in Tabriz, Iran. Pak J Med Sci  2009; 25:211- 216.
10. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns 2009; 36:70- 74.                                                                                                         
11. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, et al. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother  2005; 56:122-127. 
12. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11:17-32.    
13. Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante G, Perilli M. Spread of bla (CTX-M-type) and bla (PER-2) beta-lactamase genes in clinical isolates from Bolivian Hospitals. J Antimicrob Chemother 2006; 57:975-978.                                                                                                                   
14. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health 2005; 36:1503-1509.    
15. Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H; Study Group. PER-1 is still widespread in Turkish Hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249:241-245.